Neuroprotective effects of selective beta-1 adrenoceptor antagonists, landiolol and esmolol, on transient forebrain ischemia in rats; A dose-response study

Brain Research

Volumn 1461, Issue , 2012, Pages 96-101

  Goyagi, Toru ^a   Horiguchi, Takashi ^a   Nishikawa, Toshiaki ^a   Tobe, Yoshitsugu ^a   Masaki, Yoko ^a  

^a AKITA UNIVERSITY   (Japan)

Author keywords

Adrenergic beta antagonist; Esmolol; Forebrain ischemia; Landiolol

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ESMOLOL; LANDIOLOL; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION SIZE; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; FOREBRAIN; HIPPOCAMPAL CA1 REGION; HISTOLOGY; MALE; NERVE CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; ISCHEMIC ATTACK, TRANSIENT; MALE; MORPHOLINES; NEUROPROTECTIVE AGENTS; PROPANOLAMINES; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; UREA;

RATTUS;

EID: 84861806294     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.04.040     Document Type: Article

References (36)

1. S. Arbabi, E.M. Campion, M.R. Hemmila, M. Barker, M. Dimo, K.S. Ahrns, A.D. Niederbichler, K. Ipaktchi, and W.L. Wahl Beta-blocker use is associated with improved outcomes in adult trauma patients J. Trauma 62 2007 56 61
2. H. Atarashi, A. Kuruma, M. Yashima, H. Saitoh, T. Ino, Y. Endoh, and H. Hayakawa Pharmocokinetics of landiolol hydrochloride, a new ultra-short-acting ß-blocker, in patients with cardiac arrhythmias Clin. Pharmacol. Ther. 68 2000 143 150
3. J.A. Capraro, D.P. Reedy, J.P. Latchaw, R.M. Slugg, N.T. Stowe, R.P. Lesser, and J.R. Littleet Treatment of acute focal cerebral ischemia with propranolol Stroke 15 1984 486 491
4. B.A. Cotton, K.B. Snodgrass, S.B. Fleming, R.O. Carpenter, C.D. Kemp, P.G. Arbogast, and J.A. Morris Jr. Beta-blocker exposure is associated with improved survival after severe traumatic brain injury J. Trauma 62 2007 26 33
5. R.G. Douglas, and J.H.F. Shaw Metabolic response to sepsis and trauma Br. J. Surg. 76 1989 115 122
6. T. Goyagi, T. Kimura, T. Nishikawa, Y. Tobe, and Y. Masaki Beta-adrenoreceptor antagonists attenuate brain injury after transient focal ischemia in rats Anesth. Analg. 103 2006 658 663
7. T. Goyagi, T. Nishikawa, Y. Tobe, and Y. Masaki The combined neuroprotective effects of lidocaine and dexmedetomidine after transient forebrain ischemia in rats Acta Anaesthesiol. Scand. 53 2009 1176 1183
8. T. Goyagi, T. Horiguchi, T. Nishikawa, and Y. Tobe Post-treatment with selective β1 adrenoceptor antagonists provides neuroprotection against transient focal ischemia in rats Brain Res. 1343 2010 213 217
9. T. Goyagi, T. Nishikawa, and Y. Tobe Neuroprotective effects and suppression of ischemia-induced glutamate elevation by β1-adrenoreceptor antagonists administered before transient focal ischemia in rats J. Neurosurg. Anesthesiol. 23 2011 131 137
10. K. Inaba, P.G. Teixeira, J.S. David, L.S. Chan, A. Salim, C. Brown, T. Browder, E. Beale, P. Rhee, and D. Demetriades Beta-blockers in isolated blunt head injury J. Am. Coll. Surg. 206 2008 432 438
11. M. Iwata, S. Inoue, M. Kawaguchi, M. Nakamura, N. Konishi, and H. Furuya Posttreatment but not pretreatment with selective beta-adrenoreceptor 1 antagonists provides neuroprotection in the hippocampus in rats subjected to transient forebrain ischemia Anesth. Analg. 110 2010 1126 1132
12. J.U. Jetschmann, R.J. Benshop, R. Jacobs, A. Kemper, J.R. Oberbeck, R.E. Schmidt, and M. Schedlowski Expression and in vivo modulation of α- and β-adrenoceptors on human natural killer (CD16) cells J. Neuroimmunol. 74 1997 159
13. I.D.A. Johnston, and R.B. Welbourn Metabolic and endocrine response to trauma Surg. Annu. 8 1976 91 101
14. L. Katz, U. Ebmeyer, P. Safar, A. Radovsky, and R. Neumar Outcome model of asphyxial cardiac arrest in rat J. Cereb. Blood Flow Metab. 15 1995 1032 1039
15. K. Ker, P. Perel, and K. Blackhall Beta-2 receptor antagonists for traumatic brain injury: a systematic review of controlled trials in animal models CNS Neurosci. Ther. 15 2009 52 64
16. S. Kimura-Kurosawa, N. Kanaya, N. Kamada, N. Hirata, M. Nakayama, and A. Namiki Cardioprotective effect and mechanism of action of landiolol on the ischemic reperfused heart J. Anesth. 21 2007 480 489
17. A. Kitamura, A. Sakamoto, T. Inoue, and R. Ogawa Efficacy of an ultrashort-acting ß-adrenoceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation Eur. J. Clin. Pharmacol. 51 1997 467 471
18. J.P. Latchaw, J.R. Little, R.M. Slugg, R.P. Lesser, and N. Stowe Treatment of acute focal cerebral ischemia and recirculation with d-propranolol Neurosurgery 16 1985 18 22
19. E.J. Ley, J. Scehnet, R. Park, S. Schroff, G. Dagliyan, P.S. Conti, D.R. Margulies, and A. Salim The in vivo effect of propranolol on cerebral perfusion and hypoxia after traumatic brain injury J. Trauma 66 2009 154 159
20. X. Liao, X. Che, W. Zhao, D. Zhang, T. Bi, and G. Wang The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signaling Oncol. Rep. 24 2010 1669 1676
21. J.R. Little, J.P. Latchaw Jr., R.M. Slugg, R.M. Slugg, R.P. Lesser, and N.T. Stowe Treatment of acute focal cerebral ischemia with propranolol Stroke 13 1982 302 307
22. E.N. McNamee, E.W. Griffin, K.M. Ryan, K.J. Ryan, S. Heffernan, A. Harkin, and T.J. Connor Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex Neuropharmacology 59 2010 37 48
23. R. Oberbeck, M. van Griensven, E. Nickel, T. Tschernig, T. Wittwer, and H.C. Pape Influence of beta-adrenoceptor antagonists on hemorrhage-induced cellular immune suppression Shock 18 2002 331 335
24. C.Y. Quon, and H.F. Stampfli Biochemical properties of blood esmolol esterase Drug Metab. Dispos. 13 1985 420 424
25. C.Y. Quon, K. Mai, G. Patil, and H.F. Stampfli Species differences in the stereoselective hydrolysis of esmolol by blood esterases Drug Metab. Dispos. 16 1988 425 428
26. W.P. Riordan Jr., B.A. Cotton, P.R. Norris, L.R. Waitman, J.M. Jenkins, and J.A. Morris Jr. Beta-blocker exposure in patients with severe traumatic brain injury (TBI) and cardiac uncoupling J. Trauma 63 2007 503 510
27. S.I. Savitz, J.A. Erhardt, J.V. Anthony, G. Gupta, X. Li, F.C. Barone, and D.M. Rosenbaum The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke J. Cereb. Blood Flow Metab. 20 2000 1197 1204
28. M. Schedlowski, W. Hosch, J.R. Oberbeck, R.J. Benshop, R. Jacobs, H.R. Raab, and R.E. Schmidt Catecholamines modulate human NK-cell circulation and function via spleen-independent β2-adrenergic mechanisms J. Immunol. 156 1996 93
29. T.J. Schroeppel, P.E. Fischer, B.L. Zarzaur, L.J. Magnotti, L.P. Clement, T.C. Fabian, and M.A. Croce Beta-adrenergic blockade and traumatic brain injury: protective? J. Trauma 69 2010 776 782
30. M. Standefer, and J.R. Little Improved neurological outcome in experimental focal cerebral ischemia treated with propranolol Neurosurgery 18 1986 136 140
31. Y. Staudt, R. Mobini, M. Fu, S.B. Felix, J.P. Kühn, and A. Staudt Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes Eur. J. Pharmacol. 466 2003 1 6
32. T.Y. Tran, I.E. Dunne, and J.W. German Beta blockers exposure and traumatic brain injury: a literature review Neurosurg. Focus. 25 2008 E8
33. F. Trudeau, and M. Milot Plasma catecholamine response in trained rats following hemorrhage Can. J. Appl. Physiol. 21 1996 481 491
34. S. Umehara, T. Goyagi, T. Nishikawa, Y. Tobe, and Y. Masaki Esmolol and landiolol, selective beta1-adrenoreceptor antagonists, provide neuroprotection against spinal cord ischemia and reperfusion in rats Anesth. Analg. 110 2010 1133 1137
35. 1-adrenoreceptor antagonist: pharmacodynamic and pharmacokinetic properties Eur. J. Clin. Pharmacol. 46 1994 399 404
36. D. Weist Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics Clin. Pharmacokinet. 28 1995 190 202